Dimethylglyoxime (DMG)

Anti-Pathogen Activity—The Landmark Finding#

The Benoit et al. (2019) study demonstrated that oral DMG is effective against multi-drug resistant (MDR) WHO priority pathogens by targeting their nickel-dependent virulence enzymes:^{[1]Benoit et al. 2019 — Nickel Chelation Therapy as an Approach to Combat Multi-Drug Resistant Enteric PathogensStéphane L. Benoit, Alan A. Schmalstig, John Glushka et al. · 2019Open reference 1 ↓}

WHO Priority Pathogen Coverage#

Among the 12 WHO critical MDR pathogens needing new antibiotics most urgently. 10 are urease-positive. 6 are hydrogenase-positive. 4 have both (hydrogenase + urease).

8 have nickel-dependent glyoxalase I.

DMG-mediated nickel chelation could be effective against the majority of the world's most dangerous antibiotic-resistant pathogens.^{[1]Benoit et al. 2019 — Nickel Chelation Therapy as an Approach to Combat Multi-Drug Resistant Enteric PathogensStéphane L. Benoit, Alan A. Schmalstig, John Glushka et al. · 2019Open reference 1 ↓}

Why This Matters for WikiBiome#

This paper is the in vivo proof that Karen's Brain Primitive 4 (Metal Dependencies as Achilles' Heels) works as a therapeutic strategy:

1. Pathogens cannot evolve around nickel dependency. Antibiotic resistance is encoded on plasmids and can be transferred horizontally. Nickel dependency is encoded in the organism's core metabolism—hydrogenase and urease are essential metalloenzymes, not accessory resistance genes. You can evolve around penicillin; you cannot evolve around needing nickel.

1. Selective chelation preserves the commensal microbiome. Most gut commensals (Bacteroidetes, Firmicutes SCFA producers) are not nickel-dependent. By targeting nickel specifically, DMG weakens pathobionts while leaving the protective microbiome intact—the opposite of broad-spectrum antibiotics.

1. This approach complements, not replaces, existing therapies. DMG weakens the pathogen's colonization machinery; the host immune system or a co-administered antibiotic finishes the job. DMG could rescue antibiotics that have lost efficacy against MDR strains.

Alzheimer's Application#

Separately, DMG has been tested against nickel-induced amyloid-beta aggregation—targeted nickel removal reduces pathological protein misfolding without stripping essential metals.^{[2]The nickel-chelator dimethylglyoxime inhibits human amyloid beta peptide in vitro aggregationBenoit SL, Bhatt RJ, Maier RJ · 2021Open reference 2 ↓} This connects the anti-pathogen and neurodegeneration applications through the same selectivity mechanism.

Nickel Contact Allergy#

DMG is also the standard dermatological spot-test reagent for detecting nickel on surfaces (jewelry, implants, tools) in Nickel Allergy and Allergic Contact Dermatitis management.^{[3]Nickel Allergy and Allergic Contact Dermatitis: A Clinical ReviewAhlström MG, Thyssen JP, Wennervaldt M et al. · 2019Open reference 3 ↓}

Cross-References#

• Nickel—the target metal
• Salmonella—hydrogenase disabled by DMG; in vivo efficacy
• Klebsiella—urease disabled by DMG
• Antimicrobial Resistance—DMG effective where antibiotics fail
• Metal Chelation Therapy—selective vs. non-selective chelation
• Nutritional Immunity (Metal Sequestration)—DMG extends host metal restriction pharmacologically
• Microbial Metallomics—the framework predicting this intervention
• Urease—nickel (Ni)-dependent enzyme disabled by DMG
• NiFe-Hydrogenase—nickel-dependent enzyme disabled by DMG
• Amyloid-Beta—nickel-dependent aggregation reduced by DMG
• Curli Amyloid Fibers—Enterobacteriaceae amyloid connection
• Competitive Exclusion—DMG weakens pathobionts, enabling commensal recovery